Bayer Signs €3 Billion Deal with Apollo for Birth Control Unit

German pharmaceutical and agricultural giant Bayer has signed a €3 billion (approximately $3.2 billion) deal to sell its birth control products unit to Apollo Global Management. According to Reuters, the sale is part of Bayer's strategic portfolio restructuring efforts. Under the agreement, Apollo will acquire certain contraceptive products from Bayer's women's health division. Bayer plans to use the cash proceeds from the transaction to reduce debt and focus on its core business segments, particularly investing in its agricultural and prescription pharmaceuticals divisions. Bayer's CEO stated that the sale aligns with the company's long-term growth strategy and will enhance shareholder value. Apollo aims to establish a strong position in the women's health market through this acquisition. The deal is expected to close in the first half of 2024. Bayer's shares saw a slight uptick on European exchanges following the announcement. This transaction is seen as part of Bayer's efforts to alleviate the high debt burden resulting from its acquisition of Monsanto in recent years. This is not investment advice.